RBC Capital Reiterates Sector Perform on Vertex Pharmaceuticals, Maintains $431 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated a Sector Perform rating for Vertex Pharmaceuticals and maintained a price target of $431.
September 19, 2024 | 2:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital has reiterated its Sector Perform rating for Vertex Pharmaceuticals, maintaining a price target of $431. This suggests a neutral outlook on the stock's performance.
The reiteration of a Sector Perform rating and maintenance of the price target at $431 by RBC Capital indicates a neutral stance on Vertex Pharmaceuticals. This suggests that the stock is expected to perform in line with the sector, and there are no significant changes in the analyst's outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100